CD8A and neoplasm: However, synergistic administration of amphiphile vaccine (amph-vax) with CAR-T cell therapy (CAR T-vax) elicited robust CD8+ T cell responses specific to the ovalbumin-derived SIINFEKL epitope while concurrently activating host T cell immunity against non-Trp1 tumor antigens (176).